Plain-English translation of NCT06112314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether combining a new medication called with a standard melanoma drug () helps people with advanced melanoma live longer and healthier than standard treatment alone. Researchers believe this medication works by training the immune system to recognize and fight melanoma cells more effectively. About 680 people will join this trial to find out which approach works best.
Advanced melanoma can be very difficult to treat, and while some patients benefit from current treatments, many do not respond well or their cancer comes back. This trial is looking to see if the new treatment can help more patients with advanced melanoma by combining two different ways of boosting the immune system to fight the cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication plus standard treatment, or standard treatment alone. If you receive the new medication, you will get infusions once a week for the first 13 weeks, then every 2 weeks until week 51, and then every 4 weeks after that. The standard treatment is given once every 4 weeks. You will visit the clinic regularly for infusions, blood tests, and imaging scans to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States